Deployment confirmed
As of 2026-08-06, Generate Biomedicines, Inc. (GENB) disclosed AI-agent language in 3 SEC filings since 2026-02-04, including 3 excerpts describing its own deployment of AI agents (source: Agentic 10-K, from SEC EDGAR).
“Strategic investments in agentic systems are enabling the platform and our new pipeline programs to advance at increased speed, scale, and efficiency.”
“We believe this integrated approach – combining a family of protein design algorithms, with experimental feedback supported by agentic systems – allows our Generate Platform to move beyond isolated model runs toward a more systematic, repeatable way of exploring protein design space.”
“We believe this integrated approach – combining a family of protein design algorithms, with experimental feedback supported by agentic systems – allows our Generate Platform to move beyond isolated model runs toward a more systematic, repeatable way of exploring protein design space.”
None identified
None named
“Strategic investments in agentic systems are enabling the platform and our new pipeline programs to advance at increased speed, scale, and efficiency.”
“We believe this integrated approach – combining a family of protein design algorithms, with experimental feedback supported by agentic systems – allows our Generate Platform to move beyond isolated model runs toward a more systematic, repeatable way of exploring protein design space.”
Generate Biomedicines made strategic investments in agentic systems to advance its platform and pipeline.
“The Generate Platform connects computational design, large-scale experimentation, and development as one system, repeatably advancing programs across multiple development paths. Strategic investments in agentic systems are enabling the platform and our new pipeline programs to advance at increased speed, scale, and efficiency.”
Generate Biomedicines uses agentic systems with protein design algorithms and experimental feedback.
“We believe this integrated approach – combining a family of protein design algorithms, with experimental feedback supported by agentic systems – allows our Generate Platform to move beyond isolated model runs toward a more systematic, repeatable way of exploring protein design space. As such, each therapeutic pursuit is valuable in and of itself, but importantly it is valuable also in building the stack of information and experience for the Generate Platform in general to enable even better future, broader applications in more reliable ways.”
Generate Biomedicines uses agentic systems with protein design algorithms and experimental feedback in its platform.
“We believe this integrated approach – combining a family of protein design algorithms, with experimental feedback supported by agentic systems – allows our Generate Platform to move beyond isolated model runs toward a more systematic, repeatable way of exploring protein design space. As such, each therapeutic pursuit is valuable in and of itself, but importantly it is valuable also in building the stack of information and experience for the Generate Platform in general to enable even better future, broader applications in more reliable ways.”